This is a routine clinical update with no material financial data or regulatory decision. Monitor for future dose-escalation results and potential partnership or financing events, but no immediate trading catalyst is present.
Price Chart
Executive Summary
Radiopharm Theranostics announced a positive DSMC recommendation to advance its radiotherapeutic RAD202 to the next dose level (180mCi) in a Phase 1 trial for HER2+ advanced solid tumors, following a prior diagnostic study showing proof-of-concept. This is a routine clinical progress update for a pre-revenue biotech with a $36M market cap; the DSMC recommendation is procedural and does not constitute a material catalyst or change the risk profile of the asset.
Key Facts
- DSMC recommended advancing RAD202 Phase 1 trial to Cohort 4 at 180mCi in HER2+ advanced solid tumors.
- Previous diagnostic study in ten HER2+ breast cancer patients showed clinical proof-of-concept with positive safety and biodistribution.
- The Phase 1 'HEAT' study is being conducted at clinical centers across Australia.
- Radiopharm has a $36M market cap and is a clinical-stage company with no approved products or revenue.
Financial Impact
No financial figures disclosed; pre-revenue clinical-stage company.
Risk Factors
- Phase 1 dose escalation does not guarantee efficacy or eventual approval.
- Radiopharm has no approved products and relies on future financing; cash runway not disclosed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3348199 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $0.9600 | awaiting T+5 | — | $0.9960 (+3.75%) |
Oct 26, 2026 1d ago | 6-K | $0.9960 | awaiting T+5 | — | $0.9960 (−0.00%) |
Oct 20, 2026 7d ago | 6-K | $0.9900 $0.9000 | ▼ −9.09% | ▼ −9.17% | $0.9960 (+0.61%) |
Oct 14, 2026 12d ago | SC 13G | $1.08 $0.9500 | ▼ −12.04% | ▼ −11.02% | $0.9960 (−7.78%) |
Oct 5, 2026 22d ago | 6-K | $1.27 $1.11 | ▼ −12.60% | ▼ −13.02% | $0.9960 (−21.57%) |
Oct 1, 2026 26d ago | 6-K | $1.48 $1.11 | ▼ −25.00% | ▼ −26.30% | $0.9960 (−32.70%) |
Sep 30, 2026 27d ago | 6-K | $1.62 $1.15 | ▼ −29.01% | ▼ −30.93% | $0.9960 (−38.52%) |
Sep 24, 2026 4w ago | EFFECT | $1.57 $1.48 | ▲ +5.85% | ▲ +5.43% | $0.9960 (+36.64%) |
Sep 22, 2026 5w ago | 6-K | $1.65 $1.52 | ▼ −7.88% | ▼ −6.69% | $0.9960 (−39.64%) |
Sep 14, 2026 6w ago | 6-K | $2.01 $1.61 | ▼ −19.90% | ▼ −20.01% | $0.9960 (−50.45%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers